1. Aberrant expression of WDR4 affects the clinical significance of cancer immunity in pan-cancer
   Hanqian Zeng et al, 2021, Aging CrossRef
2. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
   Xiaomin Zhang et al, 2022, Frontiers in Immunology CrossRef
3. Immune therapy: a new therapy for acute myeloid leukemia
   Chen Tian et al, 2023, Blood Science CrossRef
4. Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia
   Chenyu Zha et al, 2024, Therapeutic Advances in Hematology CrossRef
5. Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis
   Mahmoud M. Morsy et al, 2024, Leukemia Research CrossRef
6. Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
   Yue Huang et al, 2022, ImmunoMedicine CrossRef
7. Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)
   Chiara Cassioli et al, 2022, International Journal of Molecular Sciences CrossRef
8. A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges
   Ying Chen et al, 2023, Frontiers in Pharmacology CrossRef
9. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia
   Xiangyu Wang et al, 2024, Annals of Hematology CrossRef
10. CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?
    Daniela Damiani et al, 2024, Biomedicines CrossRef
11. CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them
    Jolien Vanhooren et al, 2023, HemaSphere CrossRef
12. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
    Diana Gumber et al, 2022, eBioMedicine CrossRef
13. Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations
    Shyam A. Patel et al, 2023, Leukemia Research CrossRef
14. Chimeric antigen receptor T-cell therapy for T-ALL and AML
    Wenwen Wei et al, 2022, Frontiers in Oncology CrossRef
15. Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming
    Maria Alvanou et al, 2023, Cancers CrossRef
16. The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity
    Yuan He et al, 2022, Cancers CrossRef
17. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
    Jiawen Huang et al, 2022, Frontiers in Immunology CrossRef
18. Progress of research on PD-1/PD-L1 in leukemia
    Huizhen Cao et al, 2023, Frontiers in Immunology CrossRef
19. Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis
    Moazzam Shahzad et al, 2023, Frontiers in Immunology CrossRef
20. Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations
    Beatriz Guijarro-Albaladejo et al, 2024, Frontiers in Cell and Developmental Biology CrossRef
21. Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances
    Martina Canichella et al, 2023, Cancers CrossRef
22. CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia—Recent Advances
    Julia Zarychta et al, 2023, Cancers CrossRef